市值管理制度 第一章 总则 第一条 为切实加强河北常山生化药业股份有限公司（以下简称"公司"） 市值管理工作，进一步规范公司市值管理行为，切实保护投资者特别是中小投资 者的合法权益，公司根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司监管指引第 10 号——市值管理》等法律、行政法规、部门规章、规 范性文件、公司股票上市地证券监管规则及《河北常山生化药业股份有限公司章 程》（以下简称"《公司章程》"）的相关规定，结合公司实际情况，制定本制度。 河北常山生化药业股份有限公司 范运作、担当责任，营造健康良好的市场生态。 第三章 市值管理的机构与职责 第五条 市值管理工作由董事会领导，董事会应当重视公司质量的提升，根 据当前业绩和未来战略规划就公司投资价值制定长期目标，在公司治理、日常经 营、并购重组及融资等重大事项决策中充分考虑投资者利益和回报，坚持稳健经 营，避免盲目扩张，不断提升上市公司投资价值。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升公 司投资价值和股东回报能力而实施的战略管理行为。 第二章 市值管理的目的与基本原则 第三条 市值管理主要目的是通过充分、合规的信息披 ...

河北常山生化药业股份有限公司 独立董事2024年度述职报告 各位股东及股东代表： 本人作为河北常山生化药业股份有限公司（以下简称"公司"）的独立董事， 在任职期间严格按照《公司法》、《证券法》、《上市公司独立董事规则》、《上市公 司治理准则》、《公司章程》、《独立董事工作制度》等相关法律、法规、规章的规 定和要求，在 2024 年度工作中，诚实、勤勉、独立地履行职责，积极出席相关 会议，认真审议董事会各项议案，对公司重大事项发表了独立意见，充分发挥了 独立董事及各专业委员会委员的作用，切实维护了公司和股东特别是中小股东的 利益，较好地发挥了独立董事的独立性和专业性作用。根据《上市公司独立董事 规则》和《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》有关要求，现将 2024 年度本人任职期间履行独立董事职责情况报告如 下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人王相君，男，中国国籍，无境外居留权，1964 年 12 月出生，本科学历， 副教授。2010 年 3 月至 2019 年 6 月，任新天绿色能源股份有限公司独立董事。 1999 年 1 月至 ...

Financial Performance - The company's revenue and net profit have significantly decreased due to the sharp decline in sales prices of heparin preparations, influenced by centralized drug procurement policies [3]. - The sales volume and prices of heparin raw materials have dropped substantially year-on-year, leading to a notable decline in both operating income and net profit [3]. - The company's operating revenue for 2024 was ¥1,030,810,532.63, a decrease of 26.92% compared to ¥1,410,439,649.66 in 2023 [17]. - The net profit attributable to shareholders for 2024 was -¥249,477,725.95, showing an improvement of 79.88% from -¥1,240,210,952.88 in 2023 [17]. - The net cash flow from operating activities increased by 66.69% to ¥56,218,170.07 in 2024, compared to ¥33,725,979.31 in 2023 [17]. - The total assets at the end of 2024 were ¥4,522,760,540.58, a decrease of 1.60% from ¥4,596,453,987.15 at the end of 2023 [17]. - The company's basic earnings per share improved to -¥0.27 in 2024 from -¥1.35 in 2023, reflecting an 80.00% increase [17]. - The weighted average return on equity for 2024 was -14.79%, an improvement of 36.13% from -50.92% in 2023 [17]. Risks and Challenges - The report highlights potential risks including policy and industry risks, intensified market competition, and risks associated with new product development [4]. - The competitive landscape for heparin raw materials is described as fierce, contributing to the price drop [3]. - The company has not provided specific forward-looking commitments, urging investors to maintain adequate risk awareness [3]. - The company faces risks related to government policies and industry regulations that could impact market competition and operational costs [96]. - The company faces risks related to centralized procurement of heparin injections, which could lead to a decline in market share if it fails to win bids [97]. Product Development and Innovation - The company is actively developing a new innovative drug, GLP-1 long-acting injection Aibennate, which has received acceptance for its marketing authorization application from NMPA [31]. - The company has successfully developed multiple proprietary heparin technologies and maintains a leading market share in low molecular weight heparin products [28]. - The company is also developing two new anti-tumor drugs, CSCJC3456 and CSCJC4523, with ongoing clinical trials [43][44]. - The company aims to expand its product line to include more polysaccharide and polypeptide products, as well as anti-tumor drugs in the coming years [36]. - The company is accelerating the clinical progress of innovative drugs, including Abenatide and anti-tumor drugs, to meet unmet clinical needs in diabetes and oncology [94]. Governance and Management - The company has established a comprehensive governance structure and internal control mechanisms to enhance decision-making and supervision [112]. - The company emphasizes strict compliance with laws and regulations regarding shareholder meetings, ensuring equal rights for all shareholders [114]. - The company maintains independent operations from its controlling shareholder, with no instances of fund occupation or guarantees provided to the controlling shareholder [115]. - The management team includes a diverse group of individuals with varying ages and backgrounds, contributing to a well-rounded leadership [126]. - The company is focused on maintaining its governance standards and ensuring compliance with regulatory requirements [125]. Environmental Compliance - The company is subject to various environmental protection laws and regulations, including the Environmental Protection Law of the People's Republic of China [163]. - 常山生化药业（江苏）有限公司严格遵守多项环境保护法律法规，确保生产过程符合国家及行业标准 [2]. - The company has implemented a hazardous waste management system and plan, complying with relevant regulations [192]. - The company treated and discharged a total of 63,238.432 tons of wastewater in 2024, with no exceedance of discharge standards [176]. - The company invested approximately 6 million RMB in environmental governance and protection in 2024, and paid an environmental protection tax of 67.63 RMB [188]. Shareholder Relations - The company has established a stable dividend policy to provide reasonable returns to shareholders [196]. - The company adheres to strict information disclosure practices, ensuring timely, accurate, and complete communication with investors [196]. - The company actively engages with investors through various communication channels to enhance transparency and credibility [196]. - The company is committed to fulfilling its social responsibilities while creating value for shareholders [196].

Financial Performance - The company's revenue for Q1 2025 was ¥258,703,492.68, a decrease of 12.10% compared to ¥294,318,791.37 in the same period last year[4] - Net profit attributable to shareholders was ¥3,782,609.17, representing a significant increase of 106.13% from a loss of ¥61,665,097.94 in the previous year[4] - Total operating revenue decreased to ¥258,703,492.68 from ¥294,318,791.37, a decline of approximately 12.1% year-over-year[17] - Net profit for the period was ¥1,627,136.62, recovering from a net loss of ¥62,005,917.65 in the previous period[18] - Operating profit turned positive at ¥2,914,348.74 compared to a loss of ¥59,521,417.38 in the prior year[18] - Total comprehensive income attributable to the parent company was 3,708,458.20, compared to a loss of 61,708,495.97 in the previous period[19] - Basic and diluted earnings per share were both 0.0041, compared to -0.0671 in the previous period, showing a significant improvement[19] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 9.61% to ¥102,992,303.02, primarily due to increased cash payments for goods and services[4] - Net cash flow from operating activities was 102,992,303.02, down from 113,942,876.84 in the previous period, representing a decrease of approximately 16.1%[21] - Cash and cash equivalents increased to ¥280,796,134.44 from ¥236,440,111.55, reflecting a growth of about 18.8%[14] - Cash and cash equivalents at the end of the period totaled 279,163,161.89, compared to 321,940,144.79 at the end of the previous period, indicating a decrease of about 13.3%[22] - Cash inflow from financing activities was 221,606,985.78, down from 507,190,717.70 in the previous period, reflecting a decline of approximately 56.4%[22] - The company reported a net cash flow from financing activities of -31,840,704.28, compared to 25,527,782.28 in the previous period, indicating a significant shift[22] - Cash outflow from investing activities was 29,165,497.16, compared to 48,605,901.53 in the previous period, indicating a decrease of about 40.2%[22] - The company experienced a foreign exchange impact on cash and cash equivalents of 1,176,593.01, compared to -208,032.64 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,548,175,452.32, reflecting a slight increase of 0.56% from ¥4,522,760,540.58 at the end of the previous year[4] - Total liabilities increased to ¥3,007,953,091.53 from ¥2,987,021,269.73, a rise of about 0.7%[15] - The company's total assets reached ¥4,548,175,452.32, up from ¥4,522,760,540.58, indicating a growth of approximately 0.6%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,446[8] - The largest shareholder, Gao Shuhua, holds 30.54% of the shares, amounting to 280,644,728 shares, with 189,189,200 shares pledged[8] - The second-largest shareholder, Yang Minghuan, holds 4.19% of the shares, totaling 38,478,022 shares, with 8,000,000 shares pledged[8] - The total number of shares held by the top 10 shareholders accounts for a significant portion of the company's equity, with the top three shareholders alone holding over 37%[8] - The total number of restricted shares at the end of the period is 2,586,014, with 397,180 shares released from restriction during the period[11] - The company has a total of 2,983,194 restricted shares held by executives, with specific release dates for some shares[11] Expenses and Cost Management - Research and development expenses decreased by 37.95% compared to the previous year, primarily due to reduced direct investment in R&D projects[6] - The company reported a significant reduction in research and development expenses to ¥10,199,286.30 from ¥16,435,989.22, a decrease of approximately 38.0%[18] - The company reported a 70.93% reduction in sales expenses, attributed to changes in marketing strategy following the entry of its main products into national procurement[6] - Total operating costs reduced to ¥262,354,455.18 from ¥355,149,467.25, a decrease of about 26.1% year-over-year[18] Financing Activities - The net cash flow from financing activities decreased by 224.73%, mainly due to a reduction in new borrowings compared to the previous year[7] - Short-term borrowings rose to ¥1,075,228,250.55 from ¥887,546,719.51, an increase of approximately 21.2%[15] Other Information - The company received government subsidies amounting to ¥416,660.72 during the reporting period, which are closely related to its normal business operations[5] - The financial statements for the quarter ending March 31, 2025, are being prepared, indicating ongoing financial reporting activities[12] - The company has not disclosed any significant new strategies or market expansions in the current reporting period[12] - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing activities[10]

常山药业(300255.SZ)公告称，修正2024年度业绩预告，预计亏损加大。原预计亏损1.2亿元–1.8亿元， 现预计亏损2.45亿元–2.55亿元。修正原因包括计提存货跌价准备约6,800万元和计提坏账准备约1,500万 元。公司将进一步加强管理和信息披露质量。 ...

Financial Performance - The company expects a net loss attributable to shareholders of between 120 million and 180 million yuan for the year 2024, compared to a net loss of 1.24021 billion yuan in the same period last year[2]. - The net loss after deducting non-recurring gains and losses is projected to be between 160 million and 220 million yuan, compared to a loss of 1.25822 billion yuan in the previous year[2]. - The company anticipates an impact of approximately 40 million yuan from non-recurring gains and losses on net profit for the reporting period[8]. Revenue and Sales - The decline in revenue is primarily due to the impact of centralized drug procurement policies, which affected the sales of the company's main product, low molecular weight heparin calcium injection[4]. - The company has significantly reduced sales expenses compared to the previous year by enhancing the precision management of market expenses[5]. Research and Development - Research and development expenses have also decreased significantly as the company focuses on advantageous projects and has completed the large-scale investment phase for some R&D projects[6].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"）与控股子公司常山凯捷 健生物药物研发（河北）有限公司于近日收到国家药品监督管理局下发的创新药 艾本那肽临床试验申请《受理通知书》，有关情况如下： 一、药品的基本情况 药物名称：艾本那肽注射液 剂型：注射液 证券代码：300255 证券简称：常山药业 公告编号：2025-6 河北常山生化药业股份有限公司 关于收到临床试验申请受理通知书的公告 注册分类：化学药品 1 类 受理号：CXHL2500378 申请的适应症：拟用于肥胖（BMI≥28kg/m²），超重（BMI>24 且<28kg/m²）伴 随至少一种体重相关合并症（以下合并简称"减重适应症"） 二、药品的其他相关情况 艾本那肽是一种长效胰高血糖素样肽-1 受体激动剂（GLP-1RA），是利用药物 亲和力偶合物（DACTM）技术，将艾塞那肽进行化学修饰后，与重组人血白蛋白 结合形成的一个全新的稳定化合物。GLP-1RA 通过激活胰高血糖素样肽-1（GLP-1） 受体以葡萄糖浓度依赖的方式刺激胰岛素分泌和抑制胰高糖素 ...

河北常山生化药业股份有限公司 关于肝素钠注射液获得坦桑尼亚药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"）于近日收到通知，公司药 品肝素钠注射液获得坦桑尼亚药品监督管理部门签发的药品注册证书，现将相关 情况公告如下： 一、药品注册文件的基本情况 证券代码：300255 证券简称：常山药业 公告编号：2025-5 有效期至：2030 年 4 月 7 日 二、药品的其他相关情况 肝素钠注射液主要用于防治血栓形成或栓塞性疾病（如心肌梗塞、血栓性静 脉炎、肺栓塞等）；各种原因引起的弥漫性血管内凝血（DIC）；也用于血液透析、 体外循环、导管术、微血管手术等操作过程及某些血液标本或器械的抗凝处理。 三、对公司的影响及风险提示 本次肝素钠注射液获得坦桑尼亚注册批文，对公司拓展海外市场带来一定积 极影响。目前公司肝素制剂产品海外销售收入占公司营业总收入比例较低。 药品销售容易受到海外市场政策环境变化、汇率波动、市场竞争等因素的影 响，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 药品名称：肝素钠注 ...

Core Viewpoint - Changshan Pharmaceutical (300255) has received a drug registration certificate for its Heparin Sodium Injection from the Tanzanian drug regulatory authority, which is primarily used for the prevention and treatment of thromboembolic diseases. The drug is valid until April 7, 2030, indicating a positive impact on the company's expansion into overseas markets [1]. Company Summary - The registration approval is expected to positively influence the company's efforts to expand its overseas market presence [1]. - Currently, the revenue from Heparin preparations in overseas sales constitutes a low percentage of the company's total operating revenue [1]. - The sales of the drug may be affected by various factors, including changes in overseas market policies, exchange rate fluctuations, and market competition [1].

证券代码：300255 证券简称：常山药业 公告编号：2025-4 河北常山生化药业股份有限公司 关于为公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"、"母公司"）于 2024 年 5 月 20 日召开的 2023 年度股东大会审议并通过《关于提供担保额度预计的议 案》，同意全资子公司河北常山凯库得生物技术有限公司（以下简称"凯库得"） 为母公司借款融资提供不超过 3.3 亿元的担保额度。额度期限自股东大会审议通 过之日起至 2024 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关 于提供担保额度预计的公告》（公告编号：2024-22）。 二、担保进展 2025 年 3 月 3 日，凯库得与渤海银行股份有限公司天津分行（以下简称"渤 海银行"）签订了《最高额保证协议》，凯库得为公司与渤海银行签订的一系列 授信协议总额度不超过人民币 2 亿元整的本金及利息等提供连带责任保证。 本次担保事项在已经审议的年度担保额度范围内，无需再提交公司董事会或 股东大会审议。 三、 ...